The Lancet Publishes Positive Results from Capricor’s Phase 2 Study of CAP-1002 in Late-Stage Duchenne
Capricor Therapeutics has announced that The Lancet has published positive results from the company’s HOPE-2 Phase 2 clinical trial evaluating CAP-1002 in advanced stages of Duchenne. Findings from the study demonstrated that young men in the advanced stages…Learn More